Citadel Advisors
PASG icon

Citadel Advisors’s Passage Bio PASG Stock Holding History

Citadel Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20
Closed -$318 – 14956
2024
Q2 		$318 Sell
20
-5
-20% -$122 ﹤0.01% 14030
2024
Q1 		$675 Buy
25
+20
+400% +$481 ﹤0.01% 14274
2023
Q4 		$101 Buy
+5
New +$69 ﹤0.01% 14130
2023
Q2 		– Sell
-70
Closed -$1.34K – 14989
2023
Q1 		$1.34K Buy
+70
New +$1.9K ﹤0.01% 14326
2021
Q4 		– Sell
-1,365
Closed -$272K – 14480
2021
Q3 		$272K Buy
1,365
+545
+66% +$130K ﹤0.01% 11268
2021
Q2 		$217K Buy
+820
New +$254K ﹤0.01% 11986

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's PASG Position: Q1 2026 in Review

Citadel Advisors sold out of Passage Bio (PASG) in Q1 2026, closing a stake of 17,660 shares — an estimated $208K sold.

Citadel Advisors first reported a position in PASG in Q1 2020 and held it in 21 quarters. The position peaked at $11.8M in Q1 2021. 35 funds tracked by Wall St. Rank hold PASG as of Q1 2026.

  • Citadel Advisors reported no remaining Passage Bio position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 17,660 Passage Bio shares in Q1 2026, an estimated $208K.
  • Citadel Advisors first reported a position in Passage Bio in Q1 2020 and held it in 21 quarters.
  • Citadel Advisors's Passage Bio position peaked at $11.8M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Passage Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.